-
Product Insights
Upper Respiratory Tract Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Upper Respiratory Tract Infections Clinical Trial Report Overview A total of 830 upper respiratory tract infections clinical trials were conducted as of October 2024. The upper respiratory tract infections clinical trial report provides a comprehensive understanding of the upper respiratory tract infections clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Analysis and Forecast to 2033
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report Overview In the 7MM, there were 62,543,523 prevalent cases of chronic obstructive pulmonary disease (COPD) in 2023. The prevalent cases of COPD will register an AGR of more than 1% during 2023-2033. Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, debilitating, and progressive disease characterized by persistent respiratory symptoms and airflow limitation. It is a common lung disorder in the aging population with systemic features ensuring morbidity and mortality in all stages...
-
Product Insights
Cystic Fibrosis - Drugs In Development, 2024
Empower your strategies with our Cystic Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose, and severe constipation. Risk factors include family history and race (Northern...
-
Product Insights
Respiratory Distress Syndrome - Drugs In Development, 2024
Empower your strategies with our Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in...
-
Product Insights
Acute Respiratory Distress Syndrome - Drugs In Development, 2024
Empower your strategies with our Acute Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia, and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure, confusion,...
-
Product Insights
Streptococcal Pneumonia - Drugs In Development, 2024
Empower your strategies with our Streptococcal Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate...
-
Product Insights
Allergic Rhinitis - Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Product Insights
Allergic Asthma - Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2024
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions. Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia (HAP) drugs in development market research report...
-
Product Insights
Acute Lung Injury - Drugs In Development, 2024
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions. Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.